Table 1.

Clinical and demographic characteristics of the study cohort. Age, disease duration, and expanded disability status scale (EDSS) score are shown as mean ± standard deviation (minimum-maximum).

Variable	Healthy controls	MS patients	P-value
Number	11	22
Number of womena	1 (9%)	17 (77%)	<0.001a
Age (years)b	34 ± 12 (22–63)	37 ± 6 (28–52)	0.19b
Disease duration (years)	N.A.	16 ± 12 (1–40)
EDSS score	N.A.	1.4 ± 1.1 (0–3.5)
MS phenotype	N.A.	Relapsing-remitting
Medical treatmentc	N.A.	21 (95%)

^aχ² test.

^bWilcoxon rank sum test.

^cMedical treatment includes Gilenya (N = 3), Ocrevus (N = 9), Tecfidera (N = 3), Tysabri (N = 4), and Copaxone (N = 2).